Matisyahu Shulman, MD

Dr Shulman is currently a co-investigator on the leadership team of two large multi-site opioid use disorder treatment trials funded through the National Institute of Health HEAL initiative. The first considers interventions to improve retention on medications for opioid use disorder and tracks outcomes in individuals who chose to discontinue medications for opioid use disorder. The second trial tests the effectiveness and implementation of a rapid approach to detoxification for induction onto long acting injectable naltrexone.

Dr Shulman also collaborates on studies considering co-morbid suicidal ideation and opioid use disorder, novel statistical methods in opioid use disorder clinical trials, comorbid pain and substance use disorders, and a multi-site trial on training clinicians in motivational interviewing.

Along with his work in clinical research Dr Shulman is actively involved in efforts to increase awareness and treatment quality for substance use disorders. He frequently lectures for both lay and clinical audiences and is on the advisory board of the Communities Confronting Substance Abuse organization (CCSA). He facilitates the CCSA support group for individuals with loved ones and family members suffering from substance use disorders.